ArticleScientific reports2020
Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- The Role of Wnt Signaling in Age-Related Alveolar Bone Loss and Regeneration.Journal of periodontal research · 2026Review
- Systemic Bone Loss and Periodontal Disease: An Updated Review of a Bidirectional Association.Dentistry journal · 2026Review
- Sclerostin antibody promotes alveolar bone regeneration after tooth extraction.Biomolecules & biomedicine · 2025Article
- Evaluation of Peri-Implant Bone Repair in Ovariectomized Rats Submitted to the Implant Placement Functionalized with Anti-Sclerostin.Bioengineering (Basel, Switzerland) · 2025Article
- Engineering a targeted and safe bone anabolic gene therapy to treat osteoporosis in alveolar bone loss.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Article
- Article
- Article
- Biomaterial design for regenerating aged bone: materiobiological advances and paradigmatic shifts.National science review · 2024Review
- Correlation between tooth decay and insulin resistance in normal weight males prompts a role for myo-inositol as a regenerative factor in dentistry and oral surgery: a feasibility study.Frontiers in bioengineering and biotechnology · 2024Article
- The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts.International journal of molecular sciences · 2023Article
- IL-1β contributes to the secretion of sclerostin by osteocytes and targeting sclerostin promotes spinal fusion at early stages.Journal of orthopaedic surgery and research · 2023Article
- Antisclerostin Effect on Osseointegration and Bone Remodeling.Journal of clinical medicine · 2023Review
- Strategies of cell and cell-free therapies for periodontal regeneration: the state of the art.Stem cell research & therapy · 2022Review
- A Bibliometric Analysis of Electrospun Nanofibers for Dentistry.Journal of functional biomaterials · 2022Review
- Titanium Nanosurface with a Biomimetic Physical Microenvironment to Induce Endogenous Regeneration of the Periodontium.ACS applied materials & interfaces · 2022Article
- Osteoporosis and periodontal diseases - An update on their association and mechanistic links.Periodontology 2000 · 2022Review
- Sclerostin is a promising therapeutic target for oral inflammation and regenerative dentistry.Journal of translational medicine · 2022Review
- Recent Advances of Therapeutic Targets for the Treatment of Periodontal Disease.Biomolecules & therapeutics · 2021Review
- Application of Implantable Polylactic-Co-Glycolic Acid Microcapsule in Repairing Alveolar Bone Defects.Evidence-based complementary and alternative medicine : eCAM · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
Abstract
Destruction of the alveolar bone in the jaws can occur due to periodontitis, trauma or following tumor resection. Common reconstructive therapy can include the use of bone grafts with limited predictability and efficacy. Romosozumab, approved by the FDA in 2019, is a humanized sclerostin-neutralizing antibody (Scl-Ab) indicated in postmenopausal women with osteoporosis at high risk for fracture. Preclinical models show that Scl-Ab administration preserves bone volume during periodontal disease, repairs bone defects surrounding dental implants, and reverses alveolar bone loss following extraction socket remodeling. To date, there are no studies evaluating Scl-Ab to repair osseous defects around teeth or to identify the efficacy of locally-delivered Scl-Ab for targeted drug delivery. In this investigation, the use of systemically-delivered versus low dose locally-delivered Scl-Ab via poly(lactic-co-glycolic) acid (PLGA) microspheres (MSs) was compared at experimentally-created alveolar bone defects in rats. Systemic Scl-Ab administration improved bone regeneration and tended to increase cementogenesis measured by histology and microcomputed tomography, while Scl-Ab delivered by MSs did not result in enhancements in bone or cemental repair compared to MSs alone or control. In conclusion, systemic administration of Scl-Ab promotes bone and cemental regeneration while local, low dose delivery did not heal periodontal osseous defects in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.